OncoSec Medical Incorporated (ONCS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ONCS • US68234L4059

0.2772 USD
+0.07 (+31.87%)
At close: Jun 23, 2023
0.23 USD
-0.05 (-17.03%)
After Hours: 6/23/2023, 8:00:02 PM
Fundamental Rating

0

Taking everything into account, ONCS scores 0 out of 10 in our fundamental rating. ONCS was compared to 525 industry peers in the Biotechnology industry. ONCS may be in some trouble as it scores bad on both profitability and health. ONCS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ONCS has reported negative net income.
  • In the past year ONCS has reported a negative cash flow from operations.
ONCS Yearly Net Income VS EBIT VS OCF VS FCFONCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

  • ONCS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONCS Yearly ROA, ROE, ROICONCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

  • ONCS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCS Yearly Profit, Operating, Gross MarginsONCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

  • ONCS has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ONCS has a worse debt to assets ratio.
ONCS Yearly Shares OutstandingONCS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ONCS Yearly Total Debt VS Total AssetsONCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -59.67, we must say that ONCS is in the distress zone and has some risk of bankruptcy.
  • ONCS has a Altman-Z score of -59.67. This is amonst the worse of the industry: ONCS underperforms 92.77% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.67
ROIC/WACCN/A
WACCN/A
ONCS Yearly LT Debt VS Equity VS FCFONCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

  • ONCS has a Current Ratio of 0.89. This is a bad value and indicates that ONCS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.89, ONCS is doing worse than 88.91% of the companies in the same industry.
  • A Quick Ratio of 0.89 indicates that ONCS may have some problems paying its short term obligations.
  • ONCS's Quick ratio of 0.89 is on the low side compared to the rest of the industry. ONCS is outperformed by 87.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.89
ONCS Yearly Current Assets VS Current LiabilitesONCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 39.16% over the past year.
EPS 1Y (TTM)39.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.37%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCS Yearly EPS VS EstimatesONCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ONCS. In the last year negative earnings were reported.
  • Also next year ONCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCS Price Earnings VS Forward Price EarningsONCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCS Per share dataONCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ONCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OncoSec Medical Incorporated / ONCS FAQ

What is the ChartMill fundamental rating of OncoSec Medical Incorporated (ONCS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ONCS.


What is the valuation status for ONCS stock?

ChartMill assigns a valuation rating of 0 / 10 to OncoSec Medical Incorporated (ONCS). This can be considered as Overvalued.


What is the profitability of ONCS stock?

OncoSec Medical Incorporated (ONCS) has a profitability rating of 1 / 10.


How financially healthy is OncoSec Medical Incorporated?

The financial health rating of OncoSec Medical Incorporated (ONCS) is 0 / 10.


Can you provide the expected EPS growth for ONCS stock?

The Earnings per Share (EPS) of OncoSec Medical Incorporated (ONCS) is expected to grow by 87.37% in the next year.